Sorafenib was the first targeted therapy to extend survival in advanced liver and kidney cancer. Despite tough side effects and limited response rates, it gave patients crucial time and paved the way for newer treatments.
A practical guide that demystifies Bethanechol clinical trials, explains key outcomes, safety data, and how to read study results for real‑world use.